ATE306555T1 - Replikationsdefizienter adenoviraler tnf vektor - Google Patents

Replikationsdefizienter adenoviraler tnf vektor

Info

Publication number
ATE306555T1
ATE306555T1 AT01950575T AT01950575T ATE306555T1 AT E306555 T1 ATE306555 T1 AT E306555T1 AT 01950575 T AT01950575 T AT 01950575T AT 01950575 T AT01950575 T AT 01950575T AT E306555 T1 ATE306555 T1 AT E306555T1
Authority
AT
Austria
Prior art keywords
adenoviral
tnf
nucleic acid
acid sequence
region
Prior art date
Application number
AT01950575T
Other languages
German (de)
English (en)
Inventor
Douglas E Brough
C Richter King
Imre Kovesdi
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Application granted granted Critical
Publication of ATE306555T1 publication Critical patent/ATE306555T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01950575T 2000-06-27 2001-06-27 Replikationsdefizienter adenoviraler tnf vektor ATE306555T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/604,694 US6579522B1 (en) 2000-06-27 2000-06-27 Replication deficient adenoviral TNF vector
PCT/US2001/020536 WO2002000906A2 (en) 2000-06-27 2001-06-27 Replication deficient adenoviral tnf vector

Publications (1)

Publication Number Publication Date
ATE306555T1 true ATE306555T1 (de) 2005-10-15

Family

ID=24420637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01950575T ATE306555T1 (de) 2000-06-27 2001-06-27 Replikationsdefizienter adenoviraler tnf vektor

Country Status (8)

Country Link
US (2) US6579522B1 (https=)
EP (1) EP1294918B1 (https=)
JP (2) JP2004501650A (https=)
AT (1) ATE306555T1 (https=)
AU (2) AU7154901A (https=)
CA (1) CA2412637A1 (https=)
DE (1) DE60114006T2 (https=)
WO (1) WO2002000906A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1180159T3 (da) * 1999-05-28 2008-11-17 Targeted Genetics Corp Fremgangsmåder og sammensætninger til at sænke niveauet af Tumor-Nekrose-Faktor (TNF) i TNF-associerede lidelser
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US6845929B2 (en) * 2002-03-22 2005-01-25 Ali Dolatabadi High efficiency nozzle for thermal spray of high quality, low oxide content coatings
US20030223962A1 (en) * 2002-06-03 2003-12-04 Cornell Research Foundation, Inc. Delivery of gene products to the lung parenchyma via gene transfer to the pleura
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
CN101507822B (zh) * 2003-11-24 2012-06-06 坎吉有限公司 皮肤瘢痕形成的减少
EP1784493A2 (en) * 2004-09-01 2007-05-16 The Government of the United States of America as Represented by The Department of Health and Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
AU2006297112B2 (en) * 2005-10-01 2013-04-18 Charles Stout Regulatable fusion promoters
DE602008004476D1 (de) * 2007-03-09 2011-02-24 Vectorlogics Inc Zellen für adenovirusvektor- und proteinherstellung
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
WO2012006145A2 (en) * 2010-06-29 2012-01-12 The Johns Hopkins University Com positions and methods for retargeting virus constructs
KR101429696B1 (ko) 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
WO2024233783A1 (en) 2023-05-09 2024-11-14 Cornell University Expression cassette coding for vascular endothelial growth factor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5763209A (en) 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
JP3443119B2 (ja) * 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1992011033A1 (en) 1990-12-20 1992-07-09 Arch Development Corporation Control of gene expression by ionizing radiation
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5968735A (en) 1992-11-12 1999-10-19 Max Delbruck-Centrum Fur Molekular Medizin Berlin Vector for the expression of therapy-relevant genes
FR2709309B1 (fr) 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5641755A (en) 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5571797A (en) 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
ATE336587T1 (de) 1994-06-10 2006-09-15 Genvec Inc Adenoviren-vektor systeme und zelllinien
US5962424A (en) 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
AU4994596A (en) 1995-03-01 1996-09-18 Cornell Research Foundation Inc. Interdependent adenoviral vectors and methods of using same
WO1996033746A1 (en) 1995-04-28 1996-10-31 Genetic Therapy, Inc. Treatment of tumors with cells expressing interferons, tumor necrosis factors, or other cytokines
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
JPH11513390A (ja) * 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
EE9800160A (et) 1995-11-28 1998-12-15 Genvec, Inc. Vektorid ja meetodid geenide ülekandmiseks rakkudesse
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
IL120979A0 (en) 1997-06-02 1997-11-20 Interpharm Lab Ltd Glycosylated TNF
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
CA2308511C (en) 1997-10-29 2016-01-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of transfected or transduced mammalian cells for treating bone pathologies
DE19747718A1 (de) 1997-10-29 1999-05-06 Baltzer Axel Wilhelm August Dr Verfahren zur Therapie knochenresorbierender Erkrankungen mit der molekularbiologischen Methode der Gentherapie
KR20010031762A (ko) 1997-11-03 2001-04-16 추후제출 유전자요법을 위한 과열 유도 발현 벡터 및 그의 이용 방법
WO1999046371A2 (en) 1998-03-11 1999-09-16 Board Of Regents, The University Of Texas System Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
JP2002506651A (ja) 1998-03-16 2002-03-05 イントロジェン・セラピューティクス，インコーポレイテッド 多重遺伝子ベクター
AU772963B2 (en) 1998-04-24 2004-05-13 Onyx Pharmaceuticals Adenoviral vectors for treating disease
AU762615B2 (en) 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer

Also Published As

Publication number Publication date
WO2002000906A2 (en) 2002-01-03
DE60114006D1 (de) 2006-02-23
JP2004501650A (ja) 2004-01-22
US20030175245A1 (en) 2003-09-18
US6579522B1 (en) 2003-06-17
AU7154901A (en) 2002-01-08
WO2002000906A3 (en) 2002-06-06
EP1294918B1 (en) 2005-10-12
JP2012139220A (ja) 2012-07-26
CA2412637A1 (en) 2002-01-03
EP1294918A2 (en) 2003-03-26
DE60114006T2 (de) 2006-07-20
AU2001271549B2 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
ATE306555T1 (de) Replikationsdefizienter adenoviraler tnf vektor
FI852626A0 (fi) Menetelmä ihmisen tuumorinekroositekijän valmistamiseksi ja sitä koodaava DNA
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
WO1995009241A3 (fr) Therapie genique anticancereuse par modulation de la reponse immunitaire et/ou inflammatoire
ATE295889T1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
WO1995031559A3 (en) Methods of inducing gene expression by ionizing radiation
PT1623990E (pt) Composições e métodos para o tratamento de tumores
BRPI0411526A (pt) vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
DK1056873T3 (da) Fremgangsmåder til produktion af et polypeptid i en Bacillus-celle
DE69924826T8 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
PT1200590E (pt) Antigénio transmembranar lectina tipo c expresso em cancro da próstata humano e utilizações do mesmo
WO1999014327A3 (en) Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
DK0777499T3 (da) Levende vaccine til behandling af tumorsygdomme
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
ATE501255T1 (de) 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
DK1313850T3 (da) Nucleinsyre og tilsvarende protein med navnet 85PB3 anvendelige til behandling og påvisning af cancer
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung
DE60134956D1 (de) Gene differentiell experimiert in brudtkrebs
ES8802250A1 (es) Un metodo para producir factor de necrosis de tumores.
WO2003047634A3 (en) Nucleic acids and methods for treating ebv-positive cancers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties